RecruitingNot applicableNCT05345158
R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma
Studying Germ cell tumor of testis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Health Network, Toronto
- Principal Investigator
- Robert Hamilton, MDThe Princess Margaret Cancer Foundation
- Intervention
- Robotic Retroperitoneal Lymph Node Dissection (RPLND)(procedure)
- Enrollment
- 25 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2022 – 2030
Study locations (1)
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05345158 on ClinicalTrials.govOther trials for Germ cell tumor of testis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07498959Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular CancerSahlgrenska University Hospital
- RECRUITINGPHASE1NCT07218913Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell TumorsCity of Hope Medical Center
- RECRUITINGPHASE2NCT06866964A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving ChemotherapyWake Forest University Health Sciences
- RECRUITINGPHASE2NCT06932458A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal MetastasesWestern University, Canada
- RECRUITINGNANCT05588700Impact of a Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor PatientsCentre Leon Berard
- RECRUITINGNCT06309745THERApy De-escalation for TESTicular CancerQueen Mary University of London
- RECRUITINGPHASE1NCT06276491Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid TumorsXencor, Inc.
- RECRUITINGNANCT06133543Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular CancerHeinrich-Heine University, Duesseldorf